DHR Q3 2025 Earnings
Reported Oct 20, 2025 at 5:39 PM ET · SEC Source
Q3 25 EPS
$1.89
BEAT +9.78%
Est. $1.72
Q3 25 Revenue
$6.05B
BEAT +0.92%
Est. $6.00B
vs S&P Since Q3 25
-18.0%
TRAILING MARKET
DHR -8.8% vs S&P +9.2%
Market Reaction
Did DHR Beat Earnings? Q3 2025 Results
Danaher delivered a strong third quarter for 2025, with both earnings and revenue clearing consensus estimates as the life sciences and diagnostics company demonstrated broadening momentum across its portfolio. Non-GAAP adjusted diluted EPS came in a… Read more Danaher delivered a strong third quarter for 2025, with both earnings and revenue clearing consensus estimates as the life sciences and diagnostics company demonstrated broadening momentum across its portfolio. Non-GAAP adjusted diluted EPS came in at $1.89, beating the $1.72 consensus by 9.78%, while revenue of $6.05 billion edged past the $6.00 billion estimate and grew 4.4% year-over-year. The standout driver was the Biotechnology segment, which posted 9.0% total sales growth fueled by continued strength in bioprocessing, helping offset a modest 1.0% core revenue decline in Life Sciences. Operating cash flow climbed to $1.66 billion from $1.51 billion a year earlier, reflecting solid execution across the business. Looking ahead, management maintained its full-year adjusted diluted EPS guidance of $7.70 to $7.80, with non-GAAP core revenue expected to grow low-single digits, while fourth-quarter guidance points to Biotechnology core growth of approximately 5% and a roughly 2.5% currency tailwind supporting reported sales.
Key Takeaways
- • Continued momentum in bioprocessing business
- • Better-than-anticipated respiratory revenue at Cepheid
- • DBS-driven execution and productivity gains
- • Favorable currency exchange rates providing 1.5% sales tailwind
DHR YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
DHR Revenue by Segment
Business unit performance breakdown
“We are encouraged by our third quarter results. DBS-driven execution paired with continued momentum in our bioprocessing business and better-than-anticipated respiratory revenue at Cepheid enabled us to exceed our revenue, earnings and cash flow expectations.”
— Rainer M. Blair, Q3 2025 Earnings Press Release
DHR Earnings Trends
DHR vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
DHR EPS Trend
Earnings per share: estimate vs actual
DHR Revenue Trend
Quarterly revenue: estimate vs actual
DHR Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $1.94 | $2.06 | +6.38% | $5.95B | -0.77% |
| Q4 25 BEAT FY | $2.19 | $2.23 | +1.79% | $6.84B | +0.42% |
| FY Full Year | — | $7.80 | — | $24.57B | — |
| Q3 25 BEAT | $1.72 | $1.89 | +9.78% | $6.05B | +0.92% |
| Q2 25 BEAT | $1.64 | $1.80 | +9.74% | $5.94B | +1.79% |